- Home
- CAPR vs LXFR Comparison
CAPR vs LXFR Comparison
Compare CAPR & LXFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- LXFR
- Stock Information
- Founded
- CAPR 2005
- LXFR 1898
- Country
- CAPR United States
- LXFR United States
- Employees
- CAPR N/A
- LXFR N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- LXFR Major Chemicals
- Sector
- CAPR Health Care
- LXFR Industrials
- Exchange
- CAPR Nasdaq
- LXFR Nasdaq
- Market Cap
- CAPR 332.5M
- LXFR 352.5M
- IPO Year
- CAPR N/A
- LXFR 2012
- Fundamental
- Price
- CAPR $18.62
- LXFR $14.22
- Analyst Decision
- CAPR Strong Buy
- LXFR
- Analyst Count
- CAPR 7
- LXFR 0
- Target Price
- CAPR $39.29
- LXFR N/A
- AVG Volume (30 Days)
- CAPR 1.1M
- LXFR 228.7K
- Earning Date
- CAPR 11-13-2024
- LXFR 10-29-2024
- Dividend Yield
- CAPR N/A
- LXFR 3.66%
- EPS Growth
- CAPR N/A
- LXFR 57.96
- EPS
- CAPR N/A
- LXFR 0.34
- Revenue
- CAPR $23,228,045.00
- LXFR $384,400,000.00
- Revenue This Year
- CAPR N/A
- LXFR N/A
- Revenue Next Year
- CAPR $135.53
- LXFR $7.30
- P/E Ratio
- CAPR N/A
- LXFR $44.88
- Revenue Growth
- CAPR 65.33
- LXFR N/A
- 52 Week Low
- CAPR $2.90
- LXFR $7.55
- 52 Week High
- CAPR $23.40
- LXFR $15.64
- Technical
- Relative Strength Index (RSI)
- CAPR 51.78
- LXFR 54.30
- Support Level
- CAPR $17.02
- LXFR $13.94
- Resistance Level
- CAPR $20.03
- LXFR $14.53
- Average True Range (ATR)
- CAPR 1.65
- LXFR 0.47
- MACD
- CAPR -0.32
- LXFR -0.12
- Stochastic Oscillator
- CAPR 51.39
- LXFR 16.47
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.
About LXFR Luxfer Holdings PLC
Luxfer Holdings PLC is a manufacturer industrial company innovating niche applications in materials engineering. It focuses on value creation by using its broad array of technical know-how and proprietary technologies to help create a safe, clean, and energy-efficient world. Luxfer's high-performance materials, components, and high-pressure gas containment devices are used in defense, first response and healthcare, transportation, and general industrial applications. It focuses on product lines related to magnesium alloys, zirconium chemicals, and carbon composites. Its segments are Elektron, Gas Cylinders, and Graphic Arts. It generates the majority of its revenue from Elektron and as well as Gas Cylinders.